Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Bank of New York Mellon Corp

Bank of New York Mellon Corp boosted its stake in Janux Therapeutics, Inc. (NASDAQ:JANX) by 13.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 89,370 shares of the company’s stock after buying an additional 10,511 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.15% of Janux Therapeutics worth $2,413,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Russell Investments Group Ltd. grew its holdings in shares of Janux Therapeutics by 77.7% in the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock valued at $54,000 after purchasing an additional 442 shares during the period. GF Fund Management CO. LTD. purchased a new stake in Janux Therapeutics in the fourth quarter valued at approximately $59,000. GAMMA Investing LLC raised its position in Janux Therapeutics by 1,574.0% in the first quarter. GAMMA Investing LLC now owns 1,674 shares of the company’s stock valued at $45,000 after purchasing an additional 1,574 shares during the period. FNY Investment Advisers LLC raised its position in Janux Therapeutics by 6,928.6% in the first quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company’s stock valued at $66,000 after purchasing an additional 2,425 shares during the period. Finally, KBC Group NV purchased a new position in shares of Janux Therapeutics in the first quarter valued at approximately $66,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Andrew Hollman Meyer sold 3,333 shares of the firm’s stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $32.03, for a total value of $106,755.99. Following the completion of the sale, the insider owned 82,139 shares in the company, valued at $2,630,912.17. This trade represents a 3.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 29.40% of the stock is currently owned by insiders.

Janux Therapeutics Stock Performance

Shares of JANX stock opened at $25.55 on Tuesday. The stock’s 50-day moving average is $24.83 and its two-hundred day moving average is $30.04. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -18.79 and a beta of 2.86. Janux Therapeutics, Inc. has a 1 year low of $22.48 and a 1 year high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.05. As a group, research analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Raymond James Financial assumed coverage on Janux Therapeutics in a research report on Friday, July 11th. They set an “outperform” rating and a $65.00 price objective on the stock. One research analyst has rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Janux Therapeutics presently has a consensus rating of “Buy” and an average price target of $91.89.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.